Ocriplasmin - Jetrea is on the market! Octo 1 2012

Ocriplasmin (JETREA®) has been approved for the treatment of symptomatic vitreomacular traction. This drug developed by Thrombogenics (of Belgium) and marketed in Europe by Alcon was first spotted by prof de Smet who approached the company in 2002 with an initial request to test its potential in eye disease. Following several initial trials (and publications), the product was developed by Thrombogenics for ocular use. In appropriate patients, it will avoid the need for surgery, as the medication itself may relieve the traction on the retina leading to the diseased state.

Prof de Smet... May 8 2012

Prof de Smet is appointed to the Ethics and Regulations in Human Research Committee of the american Association for Research in Vision and Ophthalmology (ARVO).

MIOS is accredited... Apri 1 2012

MIOS is accredited by Second Sight for the implantation of ocular prosthesis in patients with retinitis pigmentosa.

Eylea is approved... Marc 1 2012

Eylea is approved by the FDA and the EMA in the treatment of wet AMD. The data safety monitoring board was headed by prof, de Smet

1 2 3 4 5 previous next